Phase II Study of Irinotecan and Panitumumab

NCT00836277 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: Panitumumab
DRUG: Irinotecan

Sponsor

Weijing Sun, MD, FACP

Collaborators

[object Object]